PTGER4 and colorectal cancer: Treatment with TP‐16, a novel EP4 antagonist, blocked the function of IMCs (M2 macrophages and MDSCs) and enhanced cytotoxic T‐cell‐mediated colorectal cancer elimination in vivo.